Search Result

Results for "

FQ

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) CD20 (1) Opioid Receptor (15) Tyrosinase (1)
By Research Areas:	Cancer (3) Inflammation/Immunology (3) Neurological Disease (12)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P1302

Orphanin FQ(1-11)	Opioid Receptor	Neurological Disease
Orphanin FQ(1-11), a orphanin FQ or nociceptin (OFQ/N) fragment, is a potent NOP receptor (ORL-1; OP4) agonist, with a K_i of 55 nM. Orphanin FQ(1-11) has no affinity for μ, δ, κ1 and κ3 receptors (K_i>1000 nM). Orphanin FQ(1-11) is analgesic in CD-1 mice .

HY-13222

BAN ORL 24 1 Publications Verification	Opioid Receptor	Neurological Disease Cancer
BAN ORL 24 is a nociceptin/orphanin FQ (N/OFQ) peptide receptor (NOP) antagonist. BAN ORL 24 has antagonistic effect for nociceptin (NOP) receptor with K_I value of 0.24 nM in CHO cell. BAN ORL 24 can be used for the research of cancer and analgesic .

HY-P0183

Nociceptin 2 Publications Verification Orphanin FQ	Opioid Receptor	Neurological Disease
Nociceptin, a heptadecapeptide, is the endogenous ligand of the nociceptin receptor, acting as a potent anti-analgesic.

HY-107721

(±)-J-113397	Opioid Receptor	Neurological Disease
(±)-J-113397 is a potent and selective non-peptidyl ORL1 receptor antagonist with a K_i of 1.8 nM for cloned human ORL1. J-113397 inhibited nociceptin/orphanin FQ-stimulated GTPγS binding to CHO cells expressing ORL1 with an IC₅₀ value of 5.3 nM. J-113397 can be used for researching the physiological roles of nociceptin/orphanin FQ .

HY-128865

BPR1M97	Opioid Receptor	Neurological Disease
BPR1M97 is a dual-acting mu opioid receptor (MOP) and nociceptin-orphanin FQ peptide (NOP) receptor agonist with K_i values of 1.8 and 4.2 nM, respectively. BPR1M97 shows high potency and blood-brain barrier penetration, and produces potent antinociceptive effects .

HY-121889

FQ	Tyrosinase	Inflammation/Immunology
FQ is a tyrosinase inhibitor that effectively inhibits the diphenolase activity of mushroom tyrosinase (IC₅₀=120 μM). FQ can be used in the study of pigmentation .

HY-P1302A

Orphanin FQ(1-11) TFA	Opioid Receptor	Neurological Disease
Orphanin FQ(1-11) TFA, a orphanin FQ or nociceptin (OFQ/N) fragment, is a potent NOP receptor (ORL-1; OP4) agonist, with a K_i of 55 nM. Orphanin FQ(1-11) TFA has no affinity for μ, δ, κ1 and κ3 receptors (K_i>1000 nM). Orphanin FQ(1-11) TFA is analgesic in CD-1 mice .

HY-10886

MCOPPB	Opioid Receptor	Neurological Disease
MCOPPB is an orally active and selective agonist of Nociceptin/Orphanin FQ–Receptor. MCOPPB inhibits signaling through the NOP receptor in the mouse brain. MCOPPB is used in anxiety disorders research .

HY-P3839

Nocistatin	Opioid Receptor	Neurological Disease
Nocistatin, a neuropeptide, is an endogenous ligand for the orphan opioid receptor-like receptor. Nocistatin is also a functional antagonist of neuropeptide nociceptin or orphanin FQ (Noc/OFQ). Nocistatin inhibits 5-HT release via a G_i/o proteinmediated pathway. Nocistatin blocks Nociceptin (Nociceptin)-induced allodynia and hyperalgesia .

HY-122681

SR-16435	Opioid Receptor	Neurological Disease
SR-16435 is a nociceptin/orphanin FQ (NOP)/μ-opioid receptor partial agonist, with high binding affinity (NOP receptor K_i=7.49; μ-Opioid receptor K_i=2.70). SR-16435 can relieve pain .

HY-13222A

BAN ORL 24 free base	Opioid Receptor	Cancer
BAN ORL 24 free base is a nociceptin/orphanin FQ (N/OFQ) peptide receptor (NOP) antagonist. BAN ORL 24 free base has antagonistic effect for nociceptin (NOP) receptor with K_I value of 0.24 nM in CHO cell. BAN ORL 24 free base can be used for the research of cancer and analgesic .

HY-P1318

Ac-RYYRIK-NH2	Opioid Receptor	Neurological Disease
Ac-RYYRIK-NH2 is a potent and partial agonist on ORL1 transfected in CHO cells (K_d=1.5 nM) and behaves as a endogenous ligand of ORL1. Ac-RYYRIK-NH2 is a specific antagonist for the activation of G protein and competitively antagonizes the stimulation of [ ³⁵S]-GTPgS binding to G proteins by nociceptin/orphanin FQ (noc/OFQ) in membranes and sections of rat brain .

HY-P1318A

Ac-RYYRIK-NH2 TFA	Opioid Receptor	Neurological Disease
Ac-RYYRIK-NH2 TFA is a potent and partial agonist on ORL1 transfected in CHO cells (K_d=1.5 nM) and behaves as a endogenous ligand of ORL1. Ac-RYYRIK-NH2 is a specific antagonist for the activation of G protein and competitively antagonizes the stimulation of [ ³⁵S]-GTPgS binding to G proteins by nociceptin/orphanin FQ (noc/OFQ) in membranes and sections of rat brain .

HY-114072

J-113397	Opioid Receptor	Neurological Disease
J-113397 is the first potent and selective nonpeptidyl ORL1 receptor antagonist (K_i: cloned human ORL1=1.8 nM) without any agonistic effects on other opioid receptors .

HY-P99483

Blontuvetmab AT 004; VT 007	CD20 Adenosine Receptor	Cancer
Blontuvetmab (AT 004) is a caninized CD20 monoclonal antibody and is also a potent, selective, highly potent antagonist of A2aR receptor. Blontuvetmab behaves as Nociceptin (HY-P0183)/Orphanin (HY-P0183) FQ receptor (NOP) agonists displaying weak NOP affinity. Blontuvetmab inhibits 5'-N-Ethylcarboxamidoadenosine (NECA)-mediated A2aR activation and significantly reverses the ability of adenosine to suppress CD8 T cell activation, increasing levels of cytokines such as IFN-γ. Blontuvetmab Blontuvetmab can be used for the research of Canine B-cell lymphoma .

HY-P1320

[Nphe1]Nociceptin(1-13)NH2	Opioid Receptor	Inflammation/Immunology
[Nphe1]Nociceptin(1-13)NH2, a novel nociceptin/orphanin FQ (NC) endogenous ligand, is a selective and competitive ociceptin receptor antagonist without any residual agonist activity. [Nphe1]nociceptin(1-13)NH2 binds selectively to recombinant nociceptin receptors (pK_i=8.4) and antagonizes the inhibitory effects of nociceptin on cyclic AMP accumulation in CHO cells (pA₂=6.0). [Nphe1]Nociceptin(1-13)NH2 has the potential to act as an analgesic agent .

HY-P1320A

[Nphe1]Nociceptin(1-13)NH2 TFA	Opioid Receptor	Inflammation/Immunology
[Nphe1]Nociceptin(1-13)NH2, a novel nociceptin/orphanin FQ (NC) endogenous ligand, is a selective and competitive ociceptin receptor antagonist without any residual agonist activity. [Nphe1]nociceptin(1-13)NH2?binds selectively to recombinant nociceptin receptors (pK_i=8.4) and antagonizes the inhibitory effects of nociceptin on cyclic AMP accumulation in CHO cells (pA₂=6.0). [Nphe1]Nociceptin(1-13)NH2 has the potential to act as an analgesic agent .

Cat. No.	Product Name	Target	Research Area

HY-P1302

Orphanin FQ(1-11)	Opioid Receptor	Neurological Disease
Orphanin FQ(1-11), a orphanin FQ or nociceptin (OFQ/N) fragment, is a potent NOP receptor (ORL-1; OP4) agonist, with a K_i of 55 nM. Orphanin FQ(1-11) has no affinity for μ, δ, κ1 and κ3 receptors (K_i>1000 nM). Orphanin FQ(1-11) is analgesic in CD-1 mice .

HY-P0183

Nociceptin 2 Publications Verification Orphanin FQ	Opioid Receptor	Neurological Disease
Nociceptin, a heptadecapeptide, is the endogenous ligand of the nociceptin receptor, acting as a potent anti-analgesic.

HY-P1302A

Orphanin FQ(1-11) TFA	Opioid Receptor	Neurological Disease
Orphanin FQ(1-11) TFA, a orphanin FQ or nociceptin (OFQ/N) fragment, is a potent NOP receptor (ORL-1; OP4) agonist, with a K_i of 55 nM. Orphanin FQ(1-11) TFA has no affinity for μ, δ, κ1 and κ3 receptors (K_i>1000 nM). Orphanin FQ(1-11) TFA is analgesic in CD-1 mice .

HY-P3839

Nocistatin	Opioid Receptor	Neurological Disease
Nocistatin, a neuropeptide, is an endogenous ligand for the orphan opioid receptor-like receptor. Nocistatin is also a functional antagonist of neuropeptide nociceptin or orphanin FQ (Noc/OFQ). Nocistatin inhibits 5-HT release via a G_i/o proteinmediated pathway. Nocistatin blocks Nociceptin (Nociceptin)-induced allodynia and hyperalgesia .

HY-P1318

Ac-RYYRIK-NH2	Opioid Receptor	Neurological Disease
Ac-RYYRIK-NH2 is a potent and partial agonist on ORL1 transfected in CHO cells (K_d=1.5 nM) and behaves as a endogenous ligand of ORL1. Ac-RYYRIK-NH2 is a specific antagonist for the activation of G protein and competitively antagonizes the stimulation of [ ³⁵S]-GTPgS binding to G proteins by nociceptin/orphanin FQ (noc/OFQ) in membranes and sections of rat brain .

HY-P1318A

Ac-RYYRIK-NH2 TFA	Opioid Receptor	Neurological Disease
Ac-RYYRIK-NH2 TFA is a potent and partial agonist on ORL1 transfected in CHO cells (K_d=1.5 nM) and behaves as a endogenous ligand of ORL1. Ac-RYYRIK-NH2 is a specific antagonist for the activation of G protein and competitively antagonizes the stimulation of [ ³⁵S]-GTPgS binding to G proteins by nociceptin/orphanin FQ (noc/OFQ) in membranes and sections of rat brain .

HY-P1320

[Nphe1]Nociceptin(1-13)NH2	Opioid Receptor	Inflammation/Immunology
[Nphe1]Nociceptin(1-13)NH2, a novel nociceptin/orphanin FQ (NC) endogenous ligand, is a selective and competitive ociceptin receptor antagonist without any residual agonist activity. [Nphe1]nociceptin(1-13)NH2 binds selectively to recombinant nociceptin receptors (pK_i=8.4) and antagonizes the inhibitory effects of nociceptin on cyclic AMP accumulation in CHO cells (pA₂=6.0). [Nphe1]Nociceptin(1-13)NH2 has the potential to act as an analgesic agent .

HY-P1320A

[Nphe1]Nociceptin(1-13)NH2 TFA	Opioid Receptor	Inflammation/Immunology
[Nphe1]Nociceptin(1-13)NH2, a novel nociceptin/orphanin FQ (NC) endogenous ligand, is a selective and competitive ociceptin receptor antagonist without any residual agonist activity. [Nphe1]nociceptin(1-13)NH2?binds selectively to recombinant nociceptin receptors (pK_i=8.4) and antagonizes the inhibitory effects of nociceptin on cyclic AMP accumulation in CHO cells (pA₂=6.0). [Nphe1]Nociceptin(1-13)NH2 has the potential to act as an analgesic agent .

Cat. No.	Product Name	Target	Research Area

HY-P99483

Blontuvetmab AT 004; VT 007	CD20 Adenosine Receptor	Cancer
Blontuvetmab (AT 004) is a caninized CD20 monoclonal antibody and is also a potent, selective, highly potent antagonist of A2aR receptor. Blontuvetmab behaves as Nociceptin (HY-P0183)/Orphanin (HY-P0183) FQ receptor (NOP) agonists displaying weak NOP affinity. Blontuvetmab inhibits 5'-N-Ethylcarboxamidoadenosine (NECA)-mediated A2aR activation and significantly reverses the ability of adenosine to suppress CD8 T cell activation, increasing levels of cytokines such as IFN-γ. Blontuvetmab Blontuvetmab can be used for the research of Canine B-cell lymphoma .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.